Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01673074 · ClinicalTrials.gov registry record · Phase 1
HPPH and PDT for Pleural Malignancy
A Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT01673074 is a Phase 1 study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 37 participants.
The verdict
NCT01673074, a Phase 1 study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine the maximally tolerated photodynamic therapy (PDT) dose and drug-light interval of PDT using light and HPPH in patients with pleural malignancy who have undergone a maximal resection.
Interventions
- DRUG (PDT) Photodynamic therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2007-11 |
| Est. Completion | 2014-10-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01673074
The ClinicalTrials.gov registry entry for NCT01673074 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which (PDT) Photodynamic therapy is the first listed.
NCT01673074 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01673074 about?
NCT01673074 is a clinical study titled "HPPH and PDT for Pleural Malignancy". The primary objective of the study is to determine the maximally tolerated photodynamic therapy (PDT) dose and drug-light interval of PDT using light and HPPH in patients with pleural malignancy who have undergone a maximal resection.
What is the current status of trial NCT01673074?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2007-11. Estimated completion is 2014-10-08.
What interventions are being tested in trial NCT01673074?
The interventions under investigation include: (PDT) Photodynamic therapy (DRUG).
Who is sponsoring clinical trial NCT01673074?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.